2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow BCG: new trials by email Literature Review of BCG trials Research Report on BCG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder Nivolumab, BCG, BMS-986205 - Urinary Bladder Neoplasms | Phase 2 | Terminated | Bristol-Myers Squibb | 142 | 2018-08-02 | 2023-06-01 |
| A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT HS-410, Placebo, BCG - Bladder Cancer | Phase 1 / Phase 2 | Terminated | Heat Biologics | 104 | 2013-12-01 | 2020-02-17 |
Urinary Bladder Neoplasms (2) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Bristol-Myers Squibb (1) · Heat Biologics (1)
United States (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · France (1) · Hong Kong (1) · Italy (1) · Mexico (1) · Netherlands (1) · Russia (1) · Spain (1) · United Kingdom (1)
2017 (1)